Teratogenicity (including phocomelia & death to fetus). May cause peripheral neuropathy following chronic & even short-term use. Hypersensitivity. Bradycardia may occur. At least 2 types of contraception including at least 1 highly effective method (eg, IUD, hormonal contraception, tubal ligation, or vasectomy) & 1 additional effective method (eg, latex condom, diaphragm, or cervical cap) starting 1 mth prior to initiating treatment, during therapy, & continuing for 1 mth discontinuation of therapy. Perform pregnancy test w/in 24 hr prior to initiating therapy & wkly during the first 4 wk of therapy, then mthly intervals in women w/ regular menstrual cycles or every 2 wk in women w/ irregular menstrual cycles. Patients should sit upright for a few min prior to standing up from a recumbent position as Thado may cause dizziness & orthostatic hypotension. Do not initiate in absolute neutrophil count <750/mm3
. Monitor WBC & differential on an on-going basis. Examine patients mthly intervals for the first 3 mth to detect early signs of neuropathy; consider electrophysiological testing & thereafter every 6 mth. Measure viral load after the 1st & 3rd mth of treatment & every 3 mth thereafter in HIV-seropositive patients. Concomitant use w/ barbiturates, alcohol, chlorpromazine, reserpine; HIV-PIs, griseofulvin, rifampicin, rifabutin, phenytoin, or carbamazepine may reduce effect of hormonal contraceptives. Avoid driving a car or operating machinery.